



**ANNUAL GENERAL MEETING
1 NOVEMBER 2000**


Bionomics Limited

Share Price and Volume Since Listing



Comparison of Share Price Performance







Bionomics Limited

**Presentation by Dr Deborah Rathjen
CEO and Managing Director**

Annual General Meeting

1 November 2000

Mission Statement

Bionomics will exploit our broadly based gene technologies to discover, develop and sell gene-based products in the global market place.

- Our customers will be pharmaceutical and biotechnology companies involved in drug development**
- Our information will provide these companies with a source of innovation to grow their businesses**

R&D Highlights 1999-2000

Initiation of research programs following the successful float on 21 December 1999

Significant gene discoveries in our epilepsy and breast cancer programs

Filing of 4 new patent applications covering these discoveries

Recent Developments

- **Bionomics has advanced work on TSG16, a breast cancer tumour suppressor gene licensed from WCH.**
- **TSG16 may have involvement in a significant pathway controlling cellular proliferation.**
- **A worldwide patent application has now been filed on TSG16.**
- **The patent filed protects the use of TSG16 in the treatment of other conditions involving unchecked cellular proliferation including diseases with an inflammatory component such as psoriasis and scarring in wound healing.**

Bionomics Disease Targets

- Epilepsy
- Breast Cancer

These diseases have large markets with a clear need for new treatments

Epilepsy Market

- 3% of the population have epilepsy at some time in their lives
- Only 50% of epileptics have their first episode before age 20
- It is estimated that 75% of epilepsy has a strong genetic component
- Anti-epileptics world market now over US \$4 billion pa
- The anti-epileptics market is dominated by old, off patent medicines which are often poorly tolerated and have many side-effects

Epilepsy is a significant disease with a clear need for new treatments and it represents a large pharmaceutical market

Bionomics Epilepsy Gene Discovery Patents

June 1995: CHRN α 4 gene responsible for Autosomal Frontal Lobe Epilepsy (ADNFLE), Australian patent licensed from WCH.

May 2000: Identification of a second gene associated with ADNFLE; provisional patent filed.

June 2000: Identification of a new gene family involved in Idiopathic Generalised Epilepsy; provisional patent filed.

July 2000: Breakthrough in understanding of common epilepsies, leading to filing of broad provisional patent.

Bionomics is the world leader in the discovery of epilepsy genes

What Do These Patents Mean for Shareholders?

- **Bionomics is building intellectual property assets which it can license or sell to generate revenue.**
- **Bionomics has an aggressive strategy to build this intellectual property.**
- **This is the way that we are building shareholder value.**

Breast Cancer Market

- Breast cancer affects 9% of women in the western world
- This translates into 200,000 new cases pa in US with 25% mortality rate
- Current treatments are imprecise and can involve chemotherapy and serious disfiguring surgery
- Gene therapy likely to revolutionise cancer treatment

The potential market for breast cancer treatments and diagnostics based on genomics information is substantial

Bionomics Breast Cancer Gene Discovery Technologies

Tumour DNA bank

Positional cloning

Genomic DNA sequencing

High throughput mutation analysis

High throughput expression analysis

Gene transfer techniques for functional analysis

Bionomics Breast Cancer Gene Discoveries

Gene 1

- Provisional patent lodged September 1.
- Less active in breast cancer cell lines and a prostate cancer cell line.
- Highly homologous to a gene which is involved in myeloid malignancies.
- The patent protects the use of Gene 1 in breast and other cancers.

TSG16

- Gene licensed from the WCH.
- Bionomics completed patent filing for worldwide patent.
- This gene may have an involvement in a significant pathway controlling cellular proliferation in breast cancer.
- The patent also protects the use of TSG16 in other forms of cancer and other conditions for example psoriasis.

Current Status of Bionomics R&D

At listing

Gene maps

Know-how

Clinical material



Current

Patented gene discoveries

Broad patent filed on framework for the genes involved in IGE

Further gene searches underway



Future

Further gene discoveries (patents)


DNA microarray

Functional genomics

Structural genomics



STRATEGIC ALLIANCES
DRUG DISCOVERY




Financials

- Float raised \$6.4m (net of costs).
- Net cash outflow to 30 June 2000 was \$2.0m (Operating loss was \$1.4 m).
- Cash on hand at 30 June of \$4.5 m.
- Placement announced on 28 July raised \$4.7 m net of costs. Placement ratified by Shareholders at EGM on 29 September.
- Exercise of float subscriber options by 1 November 2001 expected to yield \$2.9 m.

We have the capacity to finance our current plans to at least 2003.

Future Revenue Streams From Gene Discoveries



Bionomics Score Card - 1

| Prospectus milestones –First 2 years | Result |
|---|---|
| Isolation of further genes involved in epilepsy | <ul style="list-style-type: none">• 2 new genes associated with 2 different forms of epilepsy identified• Broad framework for the discovery of genes associated with IGEs patented |
| Studies that determine the function in disease of genes that are isolated | <ul style="list-style-type: none">• Studies on the isolated epilepsy genes have commenced |
| Isolation of the two tumour suppressor gene identified on chromosome 16 and other genes involved in breast cancer | <ul style="list-style-type: none">• 2 genes isolated• Work continuing to identify other candidate breast cancer genes |

Bionomics Score Card - 2

| Other objectives – First 2 years | Result |
|---|---|
| DNA microarray | The triggering of the IMVS Services agreement was delayed pending finalisation of consortium arrangements. These are now in place. |
| Attract R&D Start Grant Funding | An application has been submitted. |
| Set-up of Thebarton Laboratories | Opened on April 4 2000 (ahead of schedule). Lease runs to March 2002. |

Business Objectives for 2000-2001

- To discover and patent further genes associated with breast cancer and epilepsy, in particular the identification of all genes involved in IGEs.**
- To identify new project opportunities for Bionomics, providing a balanced research and development portfolio.**
- To establish alliances which enhance the competitive advantage of Bionomics within the genomics sector of the biotechnology industry.**
- To progress the commercial prospects for Bionomics projects.**

Bionomics Today

- **Globally competitive science**
- **Broadly-based genomics platform**
- **Exclusive access to clinical material**
- **Rapidly expanding patent portfolio**
- **Bionomics is building strategic alliances which enhance our ability to be a supplier of validated drug targets**
- **Management experienced in the business of science**
- **Financial capacity to carry forward our business objectives**